A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)

NAActive, not recruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

February 28, 2038

Study Completion Date

February 28, 2041

Conditions
Lumbar Spinal Stenosis
Interventions
DEVICE

Superion™ IDS device

The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.

Trial Locations (23)

10065

Weill Cornell Medical University, New York

17601

Center for Interventional Pain and Spine, Lancaster

25301

The Spine and Nerve Center of Saint Francis Hospital, Charleston

29576

SC Pain and Spine Specialists, Murrells Inlet

30326

Alliance Spine and Pain Centers, Atlanta

31501

Centurion Spine and Pain, Waycross

32607

The Orthopaedic Institute, Gainesville

33308

Holy Cross Hospital, Fort Lauderdale

48198

Michigan Pain Specialists, Ypsilanti

60007

Ascension Alexian Brothers, Elk Grove Village

60612

Rush University Medical Center, Chicago

66160

University of Kansas Hospital, Kansas City

66215

Neuroscience Research Center, LLC, Overland Park

75701

Precision Spine Care, Tyler

83854

North Idaho Day Surgery, Post Falls

92009

Coastal Research Institute, LLC, Carlsbad

92270

Vitamed Research, Rancho Mirage

94598

IPM Medical Group Inc., Walnut Creek

94939

MarinHealth Spine Institute, Larkspur

97401

Pacific Sports and Spine, LLC, Eugene

98122

Swedish Health Services, Seattle

99201

Northwest Pain Care, Spokane

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT04192591 - A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE) | Biotech Hunter | Biotech Hunter